Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...

At the ITF Masters event in Bedford, NS, last month, the Canadians cleaned up by winning almost every title at the Atlantic ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

Thankfully, there are currently two RSV vaccines approved by the Food and Drug Administration to help people protect against the virus: Arexvy by GlaxoSmithKline and Abrysvo by Pfizer. The Centers for ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

The MONeT study enrolled individuals who had chronic pulmonary, cardiovascular, renal, hepatic, neurologic, hematologic or metabolic disorders. The Food and Drug Administration (FDA) has approved ...

Abrysvo is now approved for adults aged 18-59 years at increased risk for RSV due to chronic conditions, expanding its previous indications. The FDA's decision is based on a phase 3 trial showing ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

The FDA has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo for adults ages 18 to 59 who are at an increased risk of developing lower respiratory tract disease (LRTD).